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Screening of TNFα, IL-10 and TLR4 single
nucleotide polymorphisms in individuals
with asymptomatic and chronic cutaneous
leishmaniasis in Colombia: a pilot study
Angélica Mera-Ramírez1, Andrés Castillo2, Yenifer Orobio1, María Adelaida Gómez1 and Carolina Gallego-Marin1,3*
Abstract
Background: Clinical manifestations of cutaneous leishmaniasis (CL) caused by Leishmania (Viannia) range from
asymptomatic infection to self-limited, or chronic (non-healing) cutaneous lesions. Given the critical role of the
immune response in the clinical outcome of CL, it is plausible that functional polymorphisms in immune-related
genes contribute to define the clinical manifestations of human infection.
Methods: DNA samples from a retrospective cohort of individuals from an endemic area of L. V. panamensis
transmission in Colombia were used to determine the frequency of SNPs in TNFα, IL-10 and TLR4 genes. DNA
samples were obtained from 74 adult participants: 38 patients presenting chronic cutaneous leishmaniasis (CCL)
and 36 individuals with asymptomatic infection. Genotyping of TNFα-308G/A,
IL-10-819C/T, and TLR4 Asp299Gly and Thr399Ile SNPs, was conducted by PCR-restriction fragment length
polymorphisms. Allele, genotype frequencies and associations between SNPs and clinical groups were evaluated.
Results: The A allele in TNFα-308G/A SNP was found more frequently in individuals with asymptomatic infection (16%
vs 7%), whereas the CC genotype in IL-10-819 C/T SNP was more frequent in patients with CCL (34% vs. 27% in
asymptomatic individuals). No differences in allele frequencies for TLR4 SNPs were found among groups.
Conclusion: This study provides a reference base for statistical power calculation and design of association studies of
genetic polymorphisms in immune response related-genes and the pathogenesis of infections caused by L. V. panamensis.
Keywords: Cutaneous leishmaniasis, Single nucleotide polymorphism, Asymptomatic infection, Chronicity
Background
Cutaneous leishmaniasis (CL) caused by Leishmania of
the Viannia subgenus is characterized by a wide spectrum
of clinical manifestations. Infection can result in self-
limited lesions that resolve without treatment, or chronic
(non-healing) lesions lasting several years and often not
responding to conventional chemotherapy [1, 2]. In
addition, asymptomatic infection occurs in a variable but
often high proportion of residents of endemic areas for
CL [2, 3].
Polarization of Th1/Th2 responses has been shown to
determine resistance and susceptibility in murine models of
Leishmania major infection [4, 5]. However, the factors and
mechanisms that drive the different outcomes of human
infections are not fully understood. Although the immuno-
logical profile associated with disease susceptibility or resist-
ance to L. Viannia infection remains unknown, correlations
between pro- and anti-inflammatory cytokine production
and clinical manifestations have been observed. High TNFα
production has been shown to contribute to parasite
control in early stages of L. V. braziliensis infection, and
exacerbation in later stages [1, 6, 7]. Higher levels of TNFα
and IL-10 secretion are detected after in vitro recall re-
sponses of mononuclear cells from individuals with chronic
and recurrent L. V. panamensis infection, compared to
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asymptomatic individuals (Navas, A. et.al, unpublished ob-
servations). Likewise, high levels of IL-10 have been de-
tected in individuals with active and chronic CL caused by
L.V. braziliensis [8–10], while low secretion has been de-
scribed during asymptomatic infection or spontaneous
healing [11].
Toll-like receptors (TLR)-ligand interactions initiate
signal transduction cascades that subsequently result in
transcription of inflammatory mediators and cytokines
such IL-10 and TNFα [12]. TLR4 has been involved in
the control of Leishmania growth in experimental mur-
ine leishmaniasis [13–16]. We have previously reported
the involvement of TLR4 in TNFα production in human
macrophages in response to L.V. panamensis infection,
and its participation in the early control of infection
[17]. Given the critical role of immune mediators in the
pathogenesis and clinical outcome of CL caused by L.
Viannia, it is plausible that functional polymorphisms in
immune-related genes contribute to define the outcome
of human infection.
Susceptibility to mucosal disease caused by L.V. brazi-
liensis has been associated with a single nucleotide poly-
morphism (SNP) in the promoter region of the TNFα
gene (-308G/A), mediating higher levels of cytokine pro-
duction [18, 19]. Similarly, high levels of IL-10 have been
associated with cutaneous lesion development during
L.V. braziliensis infection, and have been linked to the
presence of the -819C/T SNP in the IL-10 promoter
[10]. The polymorphisms 896A/G and 1196C/T (com-
monly named Asp299Gly and Thr399Ile, respectively) in
the coding region of the TLR4 gene affect the extracellu-
lar domain of the receptor impairing the ligand-binding
or protein interactions [20]. These variants have been
described as a risk factor for septic shock, infection with
Gram-negative bacteria and development of severe mal-
aria [20–22]. Genotyping of Asp299Gly and Thr399Ile
SNPs in CL caused by L. major showed a higher fre-
quency (40.9%) in patients with chronic disease com-
pared to individuals with asymptomatic infection
(13.3%) suggesting the involvement of TLR4 in suscepti-
bility and severity of CL [23].
The aim of this pilot study was to determine the
frequency of SNPs in TNFα, IL-10 and TLR4 genes
in individuals with clinical and immunological evi-
dence of Leishmania infection in endemic areas of L.
V. panamensis transmission in Colombia, and to ex-
plore its relationship with the clinical outcome of
infection.
Methods
Study design, subjects and sampling
From a database of stored human biological samples
with a total of 560 records, collected from years 2007
to 2010, a retrospective pilot case-control study was
designed to explore the frequencies of SNPs in immune
related genes and the clinical outcome of L. Viannia in-
fection, and included CCL patients (cases) and individ-
uals with asymptomatic infection (controls). Inclusion
criteria for individuals with asymptomatic infection
were defined as a positive in vitro lympho-proliferation
assay in response to Leishmania antigen [24] and no
evidence or history of dermal lesions suggestive of CL.
Patients with CCL were included if they presented
cutaneous lesions with ≥ 4 months of disease evolu-
tion, parasitological confirmation of infection by micro-
scopic examination of lesion smears or biopsy specimens
and/or parasite isolation, and/or positive Montenegro skin
test reaction (MSR) or lympho-proliferation assay,
who had not received anti-leishmanial treatment be-
fore enrollment. All subjects were of Afro-Colombian
ethnicity.
This study used DNA samples obtained from buccal
swabs (BuccalAmp, Epicentre) from patients with CCL (n
= 38) and from individuals with asymptomatic infection
(n = 36), all residents of endemic areas of L.V. panamensis
transmission in rural areas of Tumaco, Colombia. DNA
samples were obtained from the CIDEIM Biobank. Demo-
graphics of study participants are shown in Table 1.
DNA genotyping
One hundred nanograms of genomic DNA were used
for PCR amplification. Genotyping of TNFα-308G/A
(Reference SNP-rs1800629), IL-10-819C/T (rs1800871),
and TLR4, Asp299Gly (A/G) (rs4986790) and Thr399Ile
(C/T) (rs4986791) was conducted by PCR-restriction
fragment length polymorphisms (RFLP) as described
previously [10, 23, 25, 26]. Primer sequences, restriction
endonucleases and fragment sizes are presented in
Table 2. Digestion of PCR products was analyzed by
electrophoresis on a 3% agarose gel stained with eth-
idium bromide. Quality control of restriction enzymes
was conducted using PCR amplification products of
the β-globin gene from DNA isolated from THP-1 or
U937 cells.
Statistical analysis
Allele and genotype frequencies were calculated for both
study groups (CCL patients and asymptomatic individ-
uals) by direct counting. Fisher’s exact test or Chi-square
test was used to determine Hardy-Weinberg equilibrium
(HWE) and the differences between allele and genotype
frequencies, depending on the calculated expected fre-
quencies. Odds ratios and 95% confidence intervals were
calculated using logistic regression models to assess the
magnitude of association between SNPs and clinical
groups. Analyses were done using the STATA SE 12.1
software, except for differences in minor allele frequencies
(MAF), which were calculated using the prop.test function
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on R 3.1.1 software (URL http://www.R-project.org/).
p values < 0.05 were considered statistically significant.
Results
DNA samples from a total of 74 participants were analyzed.
Amplification products for TNFα genotyping were obtained
from 83.7% of samples (62 of 74), for IL-10 from 72.9% (54
of 74), and for TLR4 Asp299Gly and Thr399Ile from 89.1%
of samples (66 of 74). Samples from which PCR amplifica-
tion products were not obtained were excluded from further
analysis, and thus, the denominator for calculation of geno-
type and allele frequencies for each SNP was variable. The
distribution of the genotypic variants for TNFα-308G/A and
TLR4 Asp299Gly SNPs met the HWE (Fisher’s exact test, p
values: 0.650 and 1 respectively), whereas IL-10-819C/T did
not, (X2 test, p < 0.05). Determination HWE for the TLR4
Thr399Ile SNP was not possible due to the absence of the T
allele within the study population. Distribution of allele and
genotype frequencies is summarized in Table 3.
The frequencies of the G allele in the −308 position of
the promoter region of the TNFα gene was similar be-
tween the study groups, while the A allele was found more
frequently in individuals with asymptomatic infection
(16% vs. 7%) (Table 3). This was concordant with a higher
frequency of the heterozygous genotype found in asymp-
tomatic individuals (25%) compared to patients with
chronic CL (15%). Genotyping of the IL-10-819 C/T SNP
showed that the CC genotype was more frequent in pa-
tients with CCL (34% vs. 27% in asymptomatics), while
higher frequency of the heterozygous genotype was found
in asymptomatic individuals (32% vs. 16%). Despite this,
no significant differences in allele, genotype frequencies or
MAF values in TNFα-308G/A or IL-10-819C/T SNPs
were found between the study groups (Table 3).
Analysis of TLR4 Asp299Gly SNP showed identical fre-
quencies between groups for the AA and AG genotypes
(85 and 15%, respectively). The GG genotype was not
found in any of the study participants. All individuals pre-
sented the homozygous CC genotype at position 1196
(Thr399Ileu) of the TLR4 gene. Since the 1196 CT and TT
genotypes were not found in any participant, comparison
between groups, MAF and co-segregation analysis with
TLR4 Asp299Gly SNP could not be performed.
The presence of more than one SNP per individual
was observed in 6 asymptomatic individuals and in 7
CCL patients. No relationship between the presence of
multiple SNPs in one individual and the clinical out-
come of infection could be established.
Discussion
Polymorphisms in promoter and coding regions of cytokine
genes have shown associations with the clinical outcome
Table 1 Baseline characteristics of the study groups
Characteristic Asymptomatic
infection
(n = 36)
Chronic cutaneous
leishmaniasis
(n = 38)
Age-years. Mean (range) 43 (17–67) 31 (9–69)
Sex:
Male; % (n) 58.3 (21) 55.3 (21)
Female; % (n) 41.7 (15) 44.7 (17)
Positive lympho-proliferation
assay; % (n)
100 (36) 15.8 (6)
Montenegro skin test
zone, mm. Mean (range)
N/A 13.25 (10–18)
Number of lesion; median (range) N/A 2.2 (1–10)
Time of evolution of older
lesion, months; median (range)
N/A 16.3 (4–72)
Type of lesions: % (n)
Ulcer N/A 71.1 (27)
Plaque N/A 5.3 (2)
Nodule N/A 7.9 (3)
Not determined N/A 15.8 (6)
Patients from whom Leishmania
strains were isolated % (n)
N/A 34.2 (13)
L. V. panamensis % (n) N/A 100 (13)
Not determineda N/A 65.8 (25)
Abbreviations: N/A not applicable
aNot determined because no strain was isolated
Table 2 Primer sequences and restriction endonucleases used for RFLP analysis and fragment sizes for identification of SNPs
SNP Primers (5’-3’) Restriction endonuclease Fragment sizes (bp)
IL-10-819 C/T F, 5- TCA TTC TAT GTG CTG GAG ATG G -3 Mae III CC: 125 + 84
TT: 209
TC: 209 + 125 + 84R, 5- TTT GGG GGA AGT GGG TAA GAG T -3
TNF-α-308 G/A F, 5- AGG CAA TAG GTT TTG AGG GCC AT -3 NcoI GG: 96 + 20
AA: 116
GA: 116 + 96 + 20R, 5- ACA CTC CCC ATC CTC CCT GCT -3
TLR4 A/G
(Asp299Gly)
F, 5- GAT TAG CAT ATC TAG ACT ACT ACC TCC ATG -3 I NcoI AA: 248
GG: 222 + 26
GA: 248 + 222 + 26R, 5- GAT CAA CTT CTG AAA AAG CAT TCC CAC -3
TLR4 C/T
(Thr399Ile)
F, 5 -GGT TGC TGT TCT CAA AGT GAT TTT GGG AGA A- 3 HinfI CC: 406
TT: 380 + 26
CT: 406 + 380 + 26R, 5 -ACC TGA AGA CTG GAG AGT GAG TTA AAT GTT- 3
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and immunological responses during Leishmania infections
[10, 27]. The TNFα-308A allele has been associated with in-
creased gene expression and thereby protein production,
exacerbated inflammatory responses and tissue damage
[28]. An association between the TNFα-308G/A poly-
morphism and risk of development of mucosal disease has
been shown during L. V. braziliensis infections in Venezue-
lan CL patients [1, 6, 19]. In contrast, no relationship could
be established between this SNP and asymptomatic, self-
healing or CCL caused by L. major in an Iranian population
[27]. The divergence in the frequency of the TNFα-308A al-
lele between studies could reflect distinct mechanisms of
pathogenicity and host responses resulting from infections
with different Leishmania species [19, 27]. The observed
frequencies of the A allele in CCL patients (7%) and asymp-
tomatic individuals (16%) are comparable to those reported
for the same clinical groups (7.8 and 11.4%, respectively) in
a larger Leishmania infected population in Iran (N = 150)
[27]. Despite the differences in allele frequency, no associ-
ation with the clinical outcome of CL could be determined.
Functional studies have demonstrated that the -819C/T
SNP in the IL-10 promoter plays a role in up-regulation of
IL-10 and modification of NF-κB binding. The CC geno-
type has been associated with higher levels of IL-10 produc-
tion [10]. Presence of the C allele has been related to
increased risk of lesion development (OR = 2.5 (1.12–5.7),
p < 0.003) in L.V. braziliensis infection [10]. High levels of
IL-10 production have been described in active and chronic
Table 3 Genotype, allele frequency and MAF of TNFα, IL-10 and TLR4 gene polymorphisms in individuals with chronic and
asymptomatic cutaneous leishmaniasis
SNPs Frequency; N (%) P value OR (95% CI)
Asymptomatic CCL
TNFα-308
Genotype AA 1 (4) 0 (0) 0.45 b 0 (0–0)
GG 20 (71) 29 (85) 0.06 a 0.39 (0.14–1.05)
GA 7 (25) 5 (15) 0.30 a 1.93 (0.54–0.94)
Allele A 9 (16) 5 (7) 0.13 a 2.41 (0.76–7.67)
G 47 (87) 63 (93) 0.13 a 0.41 (0.13–1.32)
MAF 0.161 0.074 0.126 a
IL-10-819
Genotype CC 6 (27) 11 (34) 0.21 a 0.49 (0.16–1.51)
TT 9 (41) 16 (50) 0.51 a 0.69 (0.23–2.07)
CT 7 (32) 5 (16) 0.16 a 2.52 (0.68–9.33)
Allele C 19 (43) 27 (42) 0.92 a 1.04 (0.48–2.26)
T 25 (57) 37 (58) 0.92 a 0.96 (0.44–2.09)
MAF 0.568 0.578 0.918 a
TLR4 Asp299Gly
Genotype AA 28 (85) 28 (85) 0.45 b 1.25 (0.38–4.22)
GG 0 (0) 0 (0) – –
AG 5 (15) 5 (15) 0.63 b 1.00 (0.20–4.88)
Allele A 61 (92) 61 (92) 0.63 b 1.00 (0.22–4.58)
G 5 (8) 5 (8) 0.63 b 1.00 (0.22–4.58)
MAF 0.076 0.076 1.000 a
TLR4 Thr399Ile
Genotype CC 34 (100) 34 (100) – –
TT 0 (0) 0 (0) – –
CT 0 (0) 0 (0) – –
Allele C 68 (100) 68 (100) – –
T – – – –
MAF 0.000 0.000 –
a Chi square test
b Fisher exact test (one-tail)
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CL [8–10], while low cytokine levels have been related to
self-healing and asymptomatic infection caused by L.V. bra-
ziliensis [11] and L.V. panamensis (Navas, A., unpublished
observations). Although our results did not establish signifi-
cant differences in the frequency of IL-10-819C/T SNP be-
tween the study groups, a higher frequency of the -819CC
genotype in CCL patients was observed, potentially suggest-
ing a contribution to pathogenicity.
Genetic variants in TLR genes correlate with disease se-
verity of multiple infectious diseases [29]. For TLR4, two
frequently co-segregating polymorphisms (Asp299Gly and
Thr399Ile) have been shown to increase the risk of sepsis
[30], Gram-negative infections [31] and severe malaria [22].
The two polymorphic sites have been predicted to affect
ligand and co-receptor binding regions, respectively [20].
Higher frequency of the Asp299Gly polymorphism has
been reported in patients with CCL caused by L. major
compared to patients with acute disease, associating this
SNP to increased risk of disease severity [23]. In contrast,
no relationships between these functional TLR4 polymor-
phisms and susceptibility to visceral leishmaniasis in an
Iranian population could be established [26]. The homozy-
gous GG genotype for the Asp299Gly SNP was not found
among our study groups comprised of an Afro-descendant
population of the South-pacific region of Colombia,
although a frequency of 0.7 to 1.5% has been reported in a
Colombian population in the North-Center region of the
country [32]. The absence of the TT genotype for the
Thr399Ile SNP in our study group is concordant with
absence of this genotype in other Colombian populations.
Conclusions
Leishmaniasis is a complex disease and multiple host
genes are involved in the outcome of infection. Polymor-
phisms in four genes were analyzed in an attempt to over-
come the limitations of single gene polymorphism studies
reported previously in CL. However, only 13 individuals
showed more than one SNP limiting the power of a multi-
marker SNP analysis. Results presented here provide a ref-
erence base for design of prospective, power-defined gen-
etic studies to explore the relationship between immune-
related genes (either individually or as multi-marker signa-
tures), disease outcome and pathogenesis of infections
caused by L. V. panamensis.
Abbreviations
CCL: Chronic Cutaneous Leishmaniasis; CL: Cutaneous Leishmaniasis;
HWE: Hardy-Weinberg Equilibrium; MAF: Minor Allele Frequency;
MSR: Montenegro skin test reaction; RFLP: Restriction Fragment Length
Polymorphisms; SNP: Single Nucleotide Polymorphism; TLR: Toll-Like Receptor
Acknowledgments
We thank the study participants from Tumaco, Colombia. We acknowledge
the participation of the institutional BioBank of CIDEIM, especially Maryori
Vidarte, for facilitating access to the clinical samples. We thank Dr. Maria del
Mar Castro, for her contributions in processing and reviewing the clinical
records and Neal Alexander for critical review of the manuscript.
Funding
This work received support by the NIAID grant 1R21AI124171 to C.G.M., the
Departamento de Ciencia y Tecnologia-Colciencias, grant 222956933302, 410–
2013 to M.A.G., Colciencias-CIDEIM Young Investigator award 525 004022012 to
A.M.R. and NIH/Fogarty International Center training grant 5D43TW006589.
Availability of data and materials
All data generated or analyzed during this study are included in this
published article.
Authors’ contributions
CGM conceived the study. CGM AMR, MAG designed the experiments and wrote
the paper. AMR performed the experiments. AC, YO performed the statistical
analysis. All the authors read and approved the final version of the manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
This study was approved and monitored by the institutional review board for
ethical conduct of research involving human subjects of the Centro
Internacional de Entrenamiento e Investigaciones Médicas-CIDEIM (Study
code CIEIH 1118), in accordance with national (resolution 008430, República
de Colombia, Ministry of Health, 1993) and international (Declaration of
Helsinki and amendments, World Medical Association, Fortaleza, Brazil,
October 2013) guidelines.
Written informed consent was obtained from each participant before
collection of samples.
Author details
1Centro Internacional de Entrenamiento e Investigaciones Médicas-CIDEIM,
Carrera 125 #, 19-225 Cali, Colombia. 2Departamento de Biología. Facultad de
Ciencias Naturales y Exactas, Universidad del Valle, Calle 13 No, 100-00 Cali,
Colombia. 3Division of Infectious Diseases and Immunology, University of
Massachusetts Medical School, 55 Lake Avenue North, 01655 Worcester, MA,
USA.
Received: 15 September 2016 Accepted: 22 February 2017
References
1. Ribeiro-De-Jesus A, Almeida RP, Lessa H, Bacellar O, Carvalho EM. Cytokine
profile and pathology in human leishmaniasis. Braz J Med Biol Res. 1998;
31(1):143–8.
2. Weigle KA, Santrich C, Martinez F, Valderrama L, Saravia NG. Epidemiology
of cutaneous leishmaniasis in Colombia: environmental and behavioral risk
factors for infection, clinical manifestations, and pathogenicity. J Infect Dis.
1993;168(3):709–14.
3. Carvalho EM, Correia Filho D, Bacellar O, Almeida RP, Lessa H, Rocha H.
Characterization of the immune response in subjects with self-healing
cutaneous leishmaniasis. Am J Trop Med Hyg. 1995;53(3):273–7.
4. Sacks D, Noben-Trauth N. The immunology of susceptibility and resistance
to Leishmania major in mice. Nat Rev Immunol. 2002;2(11):845–58.
5. Scott P, Natovitz P, Coffman RL, Pearce E, Sher A. CD4+ T cell subsets in
experimental cutaneous leishmaniasis. Mem Inst Oswaldo Cruz. 1988;83
Suppl 1:256–9.
6. Bacellar O, Lessa H, Schriefer A, Machado P, Ribeiro de Jesus A, Dutra WO,
Gollob KJ, Carvalho EM. Up-regulation of Th1-type responses in mucosal
leishmaniasis patients. Infect Immun. 2002;70(12):6734–40.
7. Da-Cruz AM, de Oliveira MP, De Luca PM, Mendonca SC, Coutinho SG.
Tumor necrosis factor-alpha in human american tegumentary leishmaniasis.
Mem Inst Oswaldo Cruz. 1996;91(2):225–9.
8. Castellano LR, Filho DC, Argiro L, Dessein H, Prata A, Dessein A, Rodrigues V.
Th1/Th2 immune responses are associated with active cutaneous
leishmaniasis and clinical cure is associated with strong interferon-gamma
production. Hum Immunol. 2009;70(6):383–90.
9. Maurer-Cecchini A, Decuypere S, Chappuis F, Alexandrenne C, De Doncker
S, Boelaert M, Dujardin JC, Loutan L, Dayer JM, Tulliano G, et al.
Mera-Ramírez et al. BMC Infectious Diseases  (2017) 17:177 Page 5 of 6
Immunological determinants of clinical outcome in Peruvian patients with
tegumentary leishmaniasis treated with pentavalent antimonials. Infect
Immun. 2009;77(5):2022–9.
10. Salhi A, Rodrigues Jr V, Santoro F, Dessein H, Romano A, Castellano LR,
Sertorio M, Rafati S, Chevillard C, Prata A, et al. Immunological and genetic
evidence for a crucial role of IL-10 in cutaneous lesions in humans infected
with Leishmania braziliensis. J Immunol. 2008;180(9):6139–48.
11. Gomes-Silva A, de Cassia Bittar R, Dos Santos Nogueira R, Amato VS, da Silva
Mattos M, Oliveira-Neto MP, Coutinho SG, Da-Cruz AM. Can interferon-gamma
and interleukin-10 balance be associated with severity of human Leishmania
(Viannia) braziliensis infection? Clin Exp Immunol. 2007;149(3):440–4.
12. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol.
2004;4(7):499–511.
13. Kropf P, Freudenberg MA, Modolell M, Price HP, Herath S, Antoniazi S,
Galanos C, Smith DF, Muller I. Toll-like receptor 4 contributes to efficient
control of infection with the protozoan parasite Leishmania major. Infect
Immun. 2004;72(4):1920–8.
14. Kropf P, Freudenberg N, Kalis C, Modolell M, Herath S, Galanos C,
Freudenberg M, Muller I. Infection of C57BL/10ScCr and C57BL/10ScNCr
mice with Leishmania major reveals a role for Toll-like receptor 4 in the
control of parasite replication. J Leukoc Biol. 2004;76(1):48–57.
15. Ribeiro-Gomes FL, Moniz-De-Souza MC, Alexandre-Moreira MS, Dias WB,
Lopes MF, Nunes MP, Lungarella G, Dosreis GA. Neutrophils activate
macrophages for intracellular killing of Leishmania major through
recruitment of TLR4 by neutrophil elastase. J Immunol. 2007;179(6):3988–94.
16. Whitaker SM, Colmenares M, Pestana KG, Mcmahon-Pratt D. Leishmania
pifanoi proteoglycolipid complex P8 induces macrophage cytokine
production through Toll-like receptor 4. Infect Immun. 2008;76(5):2149–56.
17. Gallego C, Golenbock D, Gomez MA, Saravia NG. Toll-Like Receptors
Participate in Macrophage Activation and Intracellular Control of Leishmania
(Viannia) panamensis. Infect Immun. 2011;79(7):2871–9.
18. Blackwell JM. Tumour necrosis factor alpha and mucocutaneous
leishmaniasis. Parasitol Today. 1999;15(2):73–5.
19. Cabrera M, Shaw MA, Sharples C, Williams H, Castes M, Convit J, Blackwell
JM. Polymorphism in tumor necrosis factor genes associated with
mucocutaneous leishmaniasis. J Exp Med. 1995;182(5):1259–64.
20. Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M, Frees K, Watt
JL, Schwartz DA. TLR4 mutations are associated with endotoxin
hyporesponsiveness in humans. Nat Genet. 2000;25(2):187–91.
21. Lorenz E, Mira JP, Cornish KL, Arbour NC, Schwartz DA. A novel
polymorphism in the toll-like receptor 2 gene and its potential association
with staphylococcal infection. Infect Immun. 2000;68(11):6398–401.
22. Mockenhaupt FP, Cramer JP, Hamann L, Stegemann MS, Eckert J, Oh NR,
Otchwemah RN, Dietz E, Ehrhardt S, Schroder NW, et al. Toll-like receptor
(TLR) polymorphisms in African children: common TLR-4 variants predispose
to severe malaria. Proc Natl Acad Sci U S A. 2006;103(1):177–82.
23. Ajdary S, Ghamilouie MM, Alimohammadian MH, Riazi-Rad F, Pakzad SR.
Toll-like receptor 4 polymorphisms predispose to cutaneous leishmaniasis.
Microbes Infect. 2011;13(3):226–31.
24. Bosque F, Saravia NG, Valderrama L, Milon G. Distinct innate and acquired
immune responses to Leishmania in putative susceptible and resistant
human populations endemically exposed to L. (Viannia) panamensis
infection. Scand J Immunol. 2000;51(5):533–41.
25. Paskulin DD, Fallavena PR, Paludo FJ, Borges TJ, Picanco JB, Dias FS, Alho CS.
TNF -308G > a promoter polymorphism (rs1800629) and outcome from
critical illness. Braz J Infect Dis. 2011;15(3):231–8.
26. Rasouli M, Keshavarz M, Kalani M, Moravej A, Kiany S, Badiee P. Toll-like
receptor 4 (TLR4) polymorphisms in Iranian patients with visceral
leishmaniasis. Mol Biol Rep. 2012;39(12):10795–802.
27. Kamali-Sarvestani E, Rasouli M, Mortazavi H, Gharesi-Fard B. Cytokine gene
polymorphisms and susceptibility to cutaneous leishmaniasis in Iranian
patients. Cytokine. 2006;35(3–4):159–65.
28. Wilson AG, Symons JA, McDowell TL, Mcdevitt HO, Duff GW. Effects of a
polymorphism in the human tumor necrosis factor alpha promoter on
transcriptional activation. Proc Natl Acad Sci U S A. 1997;94(7):3195–9.
29. Schroder NW, Schumann RR. Single nucleotide polymorphisms of Toll-like
receptors and susceptibility to infectious disease. Lancet Infect Dis. 2005;5(3):156–64.
30. Lorenz E, Mira JP, Frees KL, Schwartz DA. Relevance of mutations in the
TLR4 receptor in patients with gram-negative septic shock. Arch Intern Med.
2002;162(9):1028–32.
31. Agnese DM, Calvano JE, Hahm SJ, Coyle SM, Corbett SA, Calvano SE, Lowry
SF. Human toll-like receptor 4 mutations but not CD14 polymorphisms are
associated with an increased risk of gram-negative infections. J Infect Dis.
2002;186(10):1522–5.
32. Zafra G, Florez O, Morillo CA, Echeverria LE, Martin J, Gonzalez CI.
Polymorphisms of toll-like receptor 2 and 4 genes in Chagas disease.
Mem Inst Oswaldo Cruz. 2008;103(1):27–30.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Mera-Ramírez et al. BMC Infectious Diseases  (2017) 17:177 Page 6 of 6
